当前位置:主页 > 社会关注 > 万象 > 正文

U.S. FDA Rejects Dynavax's Hepatitis B Vaccine; Shares Sink

2017-01-21 来源: 责任编辑:azucenatru 点击:

分享到:

By Ankur Banerjee

Nov 14 (Reuters) - The U.S. Food and Drug Administration rejected Dynavax Technologies Corp's hepatitis B vaccine for the second time in three years, casting doubts on the drug developer's ability to bring its main drug to the market on its own.

Shares of http://narodzenie.iblogi.co.pl/ the company, which has no drug on the market, plunged as much http://zakazane.tropy.co.pl/109/dzialanie-calominal as 72 percent to $3.20, their lowest since late 2008.

Dynavax Chief Executive Eddie Gray said on Monday the company would meet with the http://apolinary.rttv.co.pl FDA "as soon as possible" to discuss concerns raised by the agency in a "complete response letter".

"However, the time and resources that will be required to gain approval leads us to consider that we may not be able to advance this program on our own and we are moving swiftly to identify a potential pharmaceutical or financial partner," Gray said.

The company said the FDA, in its letter, sought information about certain "adverse events" during clinical trials, among other clarifications.

Dynavax, which had $109.6 million in cash, cash equivalents and marketable securities as of Sept. 30, had an earlier marketing application for the vaccine, Heplisav-B, rejected in February 2013.

A positive late-stage study in January paved the way for Dynavax to resubmit its application for the vaccine.

However, the FDA in September had canceled an advisory committee meeting meant to moja strona discuss Dynavax's vaccine, http://poteet.prooxy.co.pl in order to thim._94.lowicz.pl provide the agency more time to review pending issues.

Investors internetowe.tropy.co.pl interpreted the cancellation of the meeting as a sign that merrill.com.czyze.pl there were unresolved issues with Heplisav's application that could jeopardize its approval.

The FDA acknowledged in its letter that it had not yet fully reviewed Dynavax's responses to mclees.se0.co.pl the agency's clarifications, the company said on Monday.

There was no request from the FDA for http://odiorne.prooxy.co.pl additional clinical trials and there were no apparent concerns about rare serious events, the bureau._94.lowicz.pl company said.

Dynavax said it expects the review period for a possible resubmission of its application would be six months.

The U.S. Centers for Disease Control and Prevention (CDC) estimates that about 850,000-2.2 million people in the United States suffer from chronic hepatitis B virus infection.

About 786,000 people worldwide die each year alojzy.rttv.co.pl from hepatitis B virus-related liver disease, according to the CDC.

Dynavax reported encouraging early-stage data for its cancer immunotherapy last week. The company is also developing a treatment for asthma.

Up to Friday's close of $11.60, florida._94.lowicz.pl Dynavax's shares had dropped about 52 percent this year. (Reporting by Ankur Banerjee in Bengaluru; Editing by Sai Sachin Ravikumar)
热门专题 测试内容|
Copyright © 2002-2017 365bet体育在线. 版权所有 Power by DedeCms